Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia [Phase 2]

View source ↗

Summary

Phase 2 trial update on ALD518 for non-small cell lung cancer-related fatigue and cachexia assessing safety, efficacy, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cachexia
• Fatigue
• Non-small Cell Lung Cancer

Drugs mentioned

• ALD518

Snippet

Sponsor: CSL Behring | Conditions: NSCLC, Fatigue | Phase 2 | Status: COMPLETED